Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.
J Cancer Res Ther. 2024 Jan 1;20(1):9-16. doi: 10.4103/jcrt.jcrt_1523_23. Epub 2024 Mar 29.
Nonsmall cell lung cancer (NSCLC) predominantly affects the elderly since its incidence and mortality rates skyrocket beyond the age of 65. The landscape of NSCLC treatment has been revolutionized by immune checkpoint inhibitors (ICIs), which have emerged after a long and mostly inactive period of conventional treatment protocols. However, there is limited data on the exact effects of these chemicals on older patients, whose care can be complicated by a variety of conditions. This highlights the need to understand the efficacy of emerging cancer medicines in older patients. In this study, we will review the data of ICIs from clinical trials that were relevant to older people with NSCLC and poor performance status. We will also discuss the role of immunosenescence in immunotherapy and biomarkers in predicting the efficacy of ICIs in patients with advanced NSCLC.
非小细胞肺癌（NSCLC）主要影响老年人，因为其发病率和死亡率在 65 岁以上急剧上升。免疫检查点抑制剂（ICIs）彻底改变了 NSCLC 的治疗格局，这些抑制剂在经过长期且大部分无效的常规治疗方案后出现。然而，对于这些药物对老年患者的确切影响的数据有限，他们的治疗可能会因多种情况而变得复杂。这凸显了了解新兴癌症药物在老年患者中的疗效的必要性。在这项研究中，我们将回顾与 NSCLC 和较差表现状态的老年人相关的临床试验中关于 ICI 的数据。我们还将讨论免疫衰老在免疫治疗中的作用以及生物标志物在预测晚期 NSCLC 患者对 ICI 疗效的作用。
